⌘K
Loading ticker…
As of 2026-08-24, Filana Therapeutics, Inc. Common Stock (FLNA) has a 3-month relative strength percentile of 15 within the TickerStance CS+ADRC universe (~5,000 tickers). The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.4%, relative volume 0.40×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
FLNA is held by 2 ETFs as of May 2026. Top owner: VHT at 0.00% weight, $203K notional.
Held by 8 ETFs · $4M across latest filings · largest weight 0.27% (QQQS).
Top 2 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.00% | $203K | — |
| QQQS | 0.27% | $52K | −0.06 pp |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Not enough history to compute monthly seasonality for FLNA.